dc.contributor.author | Dolly, SO | |
dc.contributor.author | Gurden, MD | |
dc.contributor.author | Drosopoulos, K | |
dc.contributor.author | Clarke, P | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Kaye, S | |
dc.contributor.author | Workman, P | |
dc.contributor.author | Linardopoulos, S | |
dc.date.accessioned | 2017-07-14T10:48:58Z | |
dc.date.issued | 2017-09-26 | |
dc.identifier.citation | British journal of cancer, 2017, 117 (7), pp. 954 - 964 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/704 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/bjc.2017.277 | |
dc.description.abstract | BACKGROUND: F-box and WD40 repeat domain-containing 7 (FBXW7) is an E3 ubiquitin ligase involved in the ubiquitination and degradation of multiple oncogenic substrates. The tumour suppressor function is frequently lost in multiple cancers through genetic deletion and mutations in a broad range of tumours. Loss of FBXW7 functionality results in the stabilisation of multiple major oncoproteins, culminating in increased cellular proliferation and pro-survival pathways, cell cycle deregulation, chromosomal instability and altered metabolism. Currently, there is no therapy to specifically target FBXW7-deficient tumours. METHODS: We performed a siRNA kinome screen to identify synthetically lethal hits to FBXW7 deficiency. RESULTS: We identified and validated cyclin G-associated kinase (GAK) as a potential new therapeutic target. Combined loss of FBXW7 and GAK caused cell cycle defects, formation of multipolar mitoses and the induction of apoptosis. The synthetic lethal mechanism appears to be independent of clathrin-mediated receptor endocytosis function of GAK. CONCLUSIONS: These data suggest a putative therapeutic strategy for a large number of different types of human cancers with FBXW7 loss, many of which have a paucity of molecular abnormalities and treatment options. | |
dc.format | Print-Electronic | |
dc.format.extent | 954 - 964 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Cell Line, Tumor | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Sulfonamides | |
dc.subject | Ubiquitin-Protein Ligases | |
dc.subject | Protein-Serine-Threonine Kinases | |
dc.subject | Intracellular Signaling Peptides and Proteins | |
dc.subject | F-Box Proteins | |
dc.subject | Cell Cycle Proteins | |
dc.subject | Clathrin | |
dc.subject | RNA, Small Interfering | |
dc.subject | Cell Cycle | |
dc.subject | Mitosis | |
dc.subject | Apoptosis | |
dc.subject | RNA Interference | |
dc.subject | Thiazolidines | |
dc.subject | Synthetic Lethal Mutations | |
dc.subject | F-Box-WD Repeat-Containing Protein 7 | |
dc.title | RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-07-24 | |
rioxxterms.versionofrecord | 10.1038/bjc.2017.277 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 7 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Drug Target Discovery | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Drug Target Discovery | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye) | |
pubs.publication-status | Published | |
pubs.volume | 117 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Drug Target Discovery | |
icr.researchteam | Signal Transduction & Molecular Pharmacology | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
icr.researchteam | Medicine Drug Development Unit (Kaye) | |
dc.contributor.icrauthor | Drosopoulos, Konstantinos | |
dc.contributor.icrauthor | Clarke, Paul | |
dc.contributor.icrauthor | De Bono, Johann | |
dc.contributor.icrauthor | Workman, Paul | |
dc.contributor.icrauthor | Linardopoulos, Spyridon | |